VivoSim Labs, Inc. VIVS
0.12 USD 0.00 (-0.08%)
Regular-session close
0.12 0.00 -1.25%
After hours · Nov 18, 7:28 PM ET
0.1186 Day range 0.1259
0.1186 52-week range 3.40
- YTD
- -93.37%
- 1 year
- -94.64%
- Market cap
- 2.43M
- EPS (ttm)
- -4.47
- YTD return
- -93.37%
- 1-year return
- -94.64%
- Volume
- 264.66K
- Avg volume
- 953.33K
- Open
- 0.12
- Previous close
- 0.1201
- Day's range
- 0.1186 – 0.1259
- 52-week range
- 0.1186 – 3.40
No chart data for this range yet.
Fundamental scorecard
5 of 25 checks passed on VIVS’s reported financials
5of 25 checks passed
- Value 2 of 5
- Growth 0 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
VIVS Revenue — quarterly 51.00K
VIVS Net income — quarterly -475.00K
VIVS EPS — quarterly -0.03
News
VivoSim Labs to Showcase Breakthrough Multiparametric NAMkind™ Liver and Intestine Data at the 2026 American College of Toxicology (ACT) Annual Meeting VivoSim Labs Q2 EPS $(0.03) Up From $(0.98) YoY, Sales $51.000K Up From $28.000K YoY
VivoSim Labs to Showcase Multiparametric Human 3D Tissue Safety Data at the American College of Toxicology (ACT) 47th Annual Meeting VivoSim Labs Partners With Chemveda Life Sciences To Test, Screen AI-Derived Drug Compounds In VivoSim's NAMkind 3D Tissue Models
VivoSim Labs and Chemveda Life Sciences Join Forces to Put AI-Designed Drug Candidates to the Human Test VivoSim Labs To Extend Its Human Tissue Platform Beyond Toxicology With Efficacy Testing Services Built On NAMkind Disease Models Of The Liver And Intestine
VivoSim Labs Extends NAMkind Platform with Human Disease Models for Efficacy Testing and Mechanistic Biomarker Profiling
VivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing Methods
VivoSim Labs (NASDAQ:VIVS) vs. iSpecimen (NASDAQ:ISPC) Head to Head Comparison
VivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs
Your note
Sign in to keep a note on VIVS — it syncs with the Stock Master app.
